Rheumatology

Meyers J, Hoog M, Mody R, Yu M, Hasenour C, Davis KL. Burden of cardiovascular disease and cardiovascular (CV) risk in patients with Type 2 diabetes mellitus (T2DM): an analysis of a US health insurance database. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S115. doi: 10.1016/j.jval.2020.04.371


OBJECTIVES: To estimate T2DM and CV-related health care resource utilization (HCRU) and costs among patients with T2DM and cardiovascular disease (CVD; e.g., stroke) or CV risk factors (CV risk; e.g., hypertension) in the United States.

Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841


Margrey M, Yi E, Wolin D, Price M, Chirila C, Davenport E, Park Y. Recognition of inflammatory back pain by US healthcare providers and barriers to specialist referral. Poster presented at the 2019 ACR/ARP Annual Meeting; November 10, 2019. Atlanta, GA.


Michaud K, Pope J, van de Laar M, Curtis JR, Kannowski C, Mitchell S, Bell J, Workman J, Paik J, Cardoso A, Taylor PC. A systematic literature review of residual symptoms and unmet need in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021 Nov;73(11):1606-16. doi: 10.1002/acr.24369


OBJECTIVE: To evaluate the nature and burden of residual disease in rheumatoid arthritis (RA) in patients who meet treatment targets. Secondly, for those who did not meet targets, evaluate how much is due to patient symptoms.

Goyal RK, Nagar SP, Kabadi SM, Davis KL, Le H, Kaye JA. Overall survival, adverse events, and economic burden in Medicare patients with chronic lymphocytic leukemia receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 9, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement 1):796. doi: 10.1182/blood-2019-122842


Vass C, Bywall KS, Payne K. Understanding Swedish preferences for a stratified approach to treatment of rheumatoid arthritis with biologics: comparing patients and the public. Poster presented at the Nordic Health Economists Study Group (NHESG) 2018 Annual Meeting; August 2018. Tromso, Norway.


Burkard T, Huegle T, Layton JB, Glynn RJ, Bloechliger M, Frey N, Jick SS, Meier CR, Spoendlin J. The risk of incident osteoarthritis of the hand in statin initiators:a sequential cohort study. Arthritis Care Res (Hoboken). 2018 Dec;70(12):1795-805. doi: 10.1002/acr.23616


OBJECTIVE: To investigate the association between statin therapy initiation and incident hand osteoarthritis (OA).

Burkard T, Bloechliger M, Frey N, Huegle T, Layton JB, Jick SS, Meier CR, Spoendlin J. The risk of incident osteoarthritis of the hand in new users of statins: a propensity score-matched sequential cohort study. Presented at the International Society for Pharmacoepidemiology 2017 Mid-Year Meeting; April 3, 2017. London, United Kingdom.


BACKGROUND: Preclinical evidence suggests a potential protective effect of statins on the risk of hand osteoarthritis (HOA), presumably via antiinflammatory mechanisms. Since evidence from large observational studies remains scarce, we aimed to investigate the association between new statin use and incident HOA.

Dhamane AD, Ajmera M, Meyers J, Davis KL. Treatment interruption patterns among adalimumab users in a commercially insured managed care population. Poster presented at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 2017. Denver, CO. [abstract] J Manag Care Spec Pharm. 2017 Mar; 23(3a):S98.


Gossec L, Kvien TK, Conaghan PG, Ostergaard M, Canete JD, Gaillez C, Mpofu S, Sherif B, Jugl S. Relationship between improvements in fatigue and signs & symptoms of active psoriatic: arthritis a sub-analysis of a phase 3 study with secukinumab. Poster presented at the 2015 ACR/ARHP Annual Meeting; November 10, 2015. San Francisco, CA. [abstract] Arthritis Rheumatol. 2015 Sep 29; 67(Suppl 10).


Subscribe to Rheumatology

How Can We Help You?